Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

Business Editor Alan Healy reports on Ireland's enduring appeal as a location for US firms to set up shop — despite a ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) provides an ...

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Fremont, California Friday, February 14, 2025, 17:00 Hrs [IST] ...